066ATZ
066ATZ is a PIP4K2A/2B inhibitor with human PIP4K2A Ki 100 nM and PIP4K2B Ki 800 nM. 066ATZ binds to ATP-binding sites of PIP4K2A and PIP4K2B to block lipid kinase activity. 066ATZ can be used for the research of non-small cell lung cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C22H23N11OS
- Masse moléculaire:489.56
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
066ATZ (0.03-20 μM;) potently and selectively inhibits recombinant PIP4K2A (Ki = 170 nM) and PIP4K2B (Ki = 870 nM) in vitro[1].
066ATZ (0.5 μM) demonstrates high selectivity against most human protein kinases, with only CK2a and CK2a2 showing significant inhibition[1].
066ATZ (20 μM; 3 days) does not affect the in vitro growth rate of H1975* NSCLC cells[1].
066ATZ (20 μM) reduces the growth-promoting activity of M2a-polarized THP-1 macrophages towards H1975 NSCLC cells in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:H1975 NSCLC cells
-
Concentration:20 μM
-
Incubation Time:3 days
-
Result:Had no effect on the growth rate of cultured H1975 cells, with cell number fold-change matching that of DMSO-treated control cells.
066ATZ (10-100 mg/kg; i.p.; single dose; 4 consecutive daily doses) is well tolerated at doses up to 100 mg/kg in female nude mice, and causes a transient blood glucose drop at doses of 30 mg/kg and higher[1].
066ATZ (10 mg/kg; i.p.; single dose) has a short in vivo half-life of ~0.5 h in male C57BL/6 mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rag2/IL2RG double knockout (R2G2) (female, 7 weeks old, 1 × 107 H1975 cells was injected subcutaneously to establish a xenograft model)[1]
-
Dosage:100 mg/kg
-
Administration:i.p.; 5 times per week for 36 days
-
Result:Reduced average tumor volume significantly compared to vehicle control on day 24 of treatment (p < 0.01).
Showed a small increase in CD31 staining in tumor tissues, indicating enhanced angiogenesis.
-
Animal Model:nude (female)[1]
-
Dosage:10 mg/kg; 30 mg/kg; 100 mg/kg
-
Administration:i.p.; single dose; 4 consecutive daily doses (100 mg/kg only)
-
Result:Caused a transient 14% blood sugar drop 30 min after injection in the 30 mg/kg and 100 mg/kg groups, but not in the 10 mg/kg group.
Showed no difference in steady-state blood glucose after 4 consecutive daily doses of 100 mg/kg.
Did not affect body weight at a dose of 100 mg/kg.
-
Animal Model:C57BL/6 (male)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; single dose
-
Result:Reached a maximum plasma concentration (Cmax) of 2,484 ng/mL (~5.1 μM) after a single dose.
Had a half-life (t1/2) of ~0.5 h.
Chemical Information
-
Masse moléculaire 489.56
-
Formule C22H23N11OS
-
SMILES
CN1C([C@H](N(C2=NC(NC3=CN=C(S3)C4=NNN=N4)=NC=C21)C5CCCC5)CC6=NC=CC=C6)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
066ATZ Related Classifications
HY-183627 Related Classifications
Powered by Bioz